SC 13G: Biofrontera Inc.

AI Summary

SC 13G filing by Biofrontera Inc..

Risk Assessment

Risk Level: low

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 09077

Filing Documents

• biofrontera13g.htm (SC 13G) — 28KB
• 0000935836-24-000303.txt ( ) — 29KB

Ownership

Item 4. Ownership. See Items 5-9 and 11 of the cover page. The shares of Common Stock beneficially owned by the reporting person consist of 504,337 shares of Common Stock, 55 Series B-1 Convertible Preferred Stock that are convertible into 77,749 shares of Common Stock and warrants to acquire 706,813 shares of Common Stock. The Series B-1 Convertible Preferred Stock and the warrants are subject to a 9.99% beneficial ownership limitation. The percentages reported in this Schedule 13G are based on 5,089,413 shares of Common Stock outstanding as of March 19, 2024, as reported in the Registration Statement filed by the Issuer on March 20, 2024.

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group. Not applicable

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group Not applicable.

Certification

Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated:March 20, 2024 /s/ Laurence W. Lytton Laurence W. Lytton

View Full Filing

View this SC 13G filing on SEC EDGAR